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Abstract 
Background and objective: The subepithelial connective tissue graft (SCTG) is the most 
widely used procedure for the treatment of gingival recession defects. Little is known, 
however, as to whether the apposed gingival flaps are more predisposed to develop plaque-
related inflammation compared to healthy sites. This has salient clinical implications, as the 
long-term results of root coverage will depend largely on the level of inflammation of the 
grafted tissue. 
Methods: In the present split-mouth case–control study, clinical and biomolecular parameters 
were used to assess the level of inflammation of periodontal sites 12 mo after treatment with 
SCTG (test) and healthy non-treated gingivae (control) following the induction of plaque-
related gingivitis in 19 patients. 
Results: The data showed that test sites had a significantly (P < 0.05) lower gingival index 
and angulated bleeding score compared to control sites (gingival index = 1.05 ± `0.23 vs. 1.34 
`±0.47; angulated bleeding score = 0.34 ±`0.37 vs. 0.61 ± 0.39) after induction of experimental 
gingivitis, whereas the plaque index did not differ in the two groups (P > 0.05). With regard to 
the biomolecular parameters, baseline levels of the proinflammatory cytokine interleukin- 1β 
were higher in the gingival crevicular fluid of test sites. However, control sites exhibited more 
pronounced increase in the levels of interleukin-1β compared to test sites, upon plaque 
accumulation, so that the final concentration was similar in both groups. No changes were 
recorded in the gingival crevicular fluid volume. 
Conclusion: Analysis of the data demonstrates that the sites of gingival recession treated with 
SCTG develop a lower degree of plaque-induced inflammation compared to healthy gingivae. 
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This strongly suggests that SCTG does not predispose to inflammation and to further gingival 
recession and makes it a safe technique in the treatment of gingival defects. 
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Introduction 
Gingival recession - the apical shift of the gingival margin respect to cemento-enamel junction 
(CEJ) - determines an exposure of the root surface to the oral cavity (1,2).  This has major 
aesthetic consequences especially in the anterior sectors, when the disharmony is visible 
during the patient’s smile or speaking. Furthermore, the irregular outline of the gingival 
margin makes it difficult to achieve plaque control and can cause dentin hypersensitivity. 
To correct both aesthetic and functional defects associated with gingival recession, root-
coverage techniques have been developed as part of periodontal plastic surgery procedures (3). 
The subepithelial connective tissue graft (SCTG), or bilaminar technique, is the most 
predictable procedure for the treatment of gingival recession defects with a mean root 
coverage up to the 97.3% and teeth with complete root coverage up to 86.7% (4).  
The use of SCTG, proposed by Langer and Langer in 1985 (5) and modified by Bruno in 1994 
(6), provides the placement of a subepithelial connective tissue graft, directly on the exposed 
root, and a coronally advanced flap. 
At the microscopic level, the nature of the attachment between the grafted tissue and root 
surface is not completely understood. The few data from human studies indicate that a new 
connective tissue attachment can occur in the lateral and apical regions of the recession defect, 
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even with rare regeneration of bone and cementum, while a long junctional epithelium extends 
over most of the root (7,8). This kind of attachment is considered a periodontal repair and not 
regeneration, and could potentially act as a “locus minoris resistentiae” in the presence of 
detrimental environmental factors. Nothing is known, however, as to whether the SCTGs are 
at a higher risk of developing inflammation and new gingival recession compared to healthy 
sites when challenged by dental plaque. To gain insight into these understudied questions, in 
the present study we investigated the changes of clinical parameters in SCTGs 1 year after 
surgery in response to plaque accumulation, as seen in experimental gingivitis. 
The ideal area to obtain a graft with an appropriate thickness (2 mm) is the palatine mucosa in 
the premolar region where there is a well-differentiated submucosa layer in addition to the 
loose connective tissue crossed by neurovascular bundles. However, the palatine mucosa is 
fixed and inseparable from the periosteum of the hard palate by strong bands of inelastic 
connective tissue that define spaces containing mucous glands and fatty cells (9). 
Successful connective tissue graft procedures should ensure not only an esthetic integration 
between tissues but also a physiological activity of the graft in terms of sensitivity and 
immunity (10–12). We have shown previously that alteration of the epicritical and/or 
protopatical sensation was found in all the gingival sites where SCTG was performed 12 mo 
before the sensorial tests, which was possibly related to an increase of free Merkel cells in the 
grafts (13). Similarly, an altered inflammatory response of the grafted tissues could affect the 
success of SCTGs. Unfortunately, limited or no data are available about the immune 
responsiveness of the treated areas to de novo plaque accumulation. In the normal gingival 
tissue, exposure to the bacterial biofilm causes inflammation, reversible after removal of the 
plaque, which manifests by the clinical signs of gingivitis (14). Dilation and increased 
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vascular permeability leading to edema formation, associated with a color change of the 
tissues towards deep red and bleeding tendency after stimulation. The junctional epithelium is 
interrupted by a leukocyte infiltrate also present in the increased gingival crevicular fluid (15– 
19). It is possible that this process is altered in the grafted tissue areas. To investigate this 
working hypothesis, we evaluated the concentration of interleukin (IL)- 1β  in the gingival 
crevicu- lar fluid, together with gingival crevicular fluid volume. IL-1β is one of the main 
inflammatory markers identified in crevicular fluid and its expression, in addition to being 
genetically modulated (20), increases with the rise of the clinical parameters associated with 
the severity of periodontal disease (21,22). 
The aim of this split-mouth study was to compare the clinical and molecular response of 
SCTGs in gingival recession defects and healthy gingiva before and after experimental 
gingivitis. Surprisingly, analysis of the data demonstrates that the sites treated with SCTG 
develop a lower degree of plaque-related inflammation compared to healthy gingivae. 
Material and methods 
Study Population 
The recruitment of the sample occurred among patients subjected to mucogingival surgery for 
problems of aesthetics and/or sensitivity due to recessions of Miller Class I or II. 
The surgical treatment was conducted at the Department of Periodontology (Dental School, 
University of Turin), between 2006 and 2010. Ethical approval was obtained for this study. 
The surgery was performed at sites without root caries, cervical restorations of Black Class V, 
veneers or prosthetic crowns. 
Exclusion criteria for the performance of surgery were: 
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-­‐ Systemic diseases which can influence periodontal tissues (diabetes, collagen or 
immunological diseases, organ transplants); 
-­‐ Taking drugs that can induce an increase in gingival volume (anti-epileptics, calcium 
channel blockers, immunosuppressants or estroprogestogen therapy); 
-­‐ Chronic or aggressive periodontitis; 
-­‐ Pregnancy or breast-feeding. 
The operations of root coverage were scheduled at the end of the no-surgical therapy, in the 
presence of an adequate control of plaque and inflammation (Full Mouth Plaque Score <20% 
and Full Mouth Bleeding Score <20%). 
The surgical procedure of SCTG, performed by periodontists experts with additional lenses 
and instruments for micro-invasive surgery, provided the use of the bilaminar technique with 
coronally positioned flap and palatal connective tissue graft. 
Sample selection  
All patients of the study population have been recalled 12 mo from the surgery and the 
research protocol was presented to them. 
For the patients who have agreed to take part in the research, providing a written consent, it 
was verified that the exclusion criteria highlighted above did not subsist, with the addition of 
the following (23,24): 
-­‐ Probing depths above 3 mm; 
-­‐ Intake of antibiotics during the month before the start of the experimental phase; 
-­‐ Current orthodontic treatments; 
-­‐ Consumption of more than 10 cigarettes / day. 
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At the end of the selection the sample included 19 patients (nine male and 10 female, one of 
them a light smoker) from 24 to 48 years old (average 34.67 ± 8.65). 
Experimental Design  
The research was a split-mouth case-control study. Each test site, represented by a dental 
element subjected to root coverage, was combined with a healthy control untreated site.  
Clinical assessments were made 1 mo before surgery to achieve good plaque control, and then 
3, 6 , 9, and 12 mo after surgery. 
Clinical evaluations and biomolecular analysis were performed for each site at the beginning 
of the experimental phase (baseline, 12 mo after surgery) and repeated after 14 d of total 
suspension of oral hygiene by patients. 
Test and control sites selection  
Surgical procedures— Patients underwent a training session on tooth brushing 2 mo before 
surgery. The free gingival graft technique was undertaken as follows: epithelium was 
eliminated from the graft by putting the connective tissue side on a sterile plate and passing a 
blade on the epithelium side to remove the outer layer. The depth of the graft was 
homogeneous and measured approximately 1.5 mm. Wires were in vicryl 5/0 and GORE Tex 
suture with C3 needle. 
Chlorexidine 0.12% twice a day for 10 d and non-steroidal anti-inflammatory drugs for 3 d 
after surgery if needed were prescribed to all patients; they were recalled after surgery at 3, 6, 
9 mo and weekly the last month before the experimental phase (12th month). 
All surgical procedures were undertaken by the same operator to avoid biases and reduce 
variability. 
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Experimental procedures - A session of professional supragingival scaling with ultrasonic 
instrument (Air-Flow S2, Universal handpiece Piezon, tip insert A, EMS, Electro Medical 
Systems S.A., Nyon, Switzerland) was performed with all patients to achieve maximal plaque 
control, optimum gingival health and to standardize gingival baseline conditions (25). 
Moreover, all subjects were motivated and trained to oral house hygiene (roll brushing 
technique, flossing). 
Three days after the scaling, each patient was recalled and the Gingival Index (GI) (26) in the 
mid-buccal and mesial-buccal sites of examined teeth was recorded. Only the patient with 
GI=0 was entered into the experimental phase.  
Plaque Index (27), Periotron® volume of the gingival crevicular fluid (28), collected with 
absorbent strips, and Angulated Bleeding Score (AngBS) (29) were recorded at test and 
control site for baseline. 
The clinical measurements were taken over by the same operator, using a graduated 
periodontal probe (PCP15/11.5; Hu Friedy, Mfg. B.V., Rotterdam, Netherland). 
To detect the AngBS, after lightly drying the gingiva with compressed air, the periodontal 
probe was held at an angle of approximately 60° to the longitudinal axis of the tooth and in 
contact with the sulcular gingival tissues. 
After measuring the volume of GCF, the samples were prepared for the dosage of IL-1β by 
enzyme-linked immunosorbent assay test.  
After the data collection, the patients were asked not to clean the teeth or rinse the mouth for 
14 d. At the end of this period all the periodontal values and the gingival crevicular fluid 
sampling were taken again.  
	  10	  
	  
Gingival crevicular fluid sampling and volume analysis 
For the collection of GCF we used sterile paper strips (PerioPaper®; OraFlow Inc., Plainview, 
NY, USA). Briefly, each site was gently air-dried in an apico-coronal direction; the area was 
carefully isolated with cotton rolls, to avoid salivary contamination of the sample; the paper 
strip was introduced into the gingival sulcus until mild resistance was felt, whilst care was 
taken to avoid mechanical injury of the tissues. The strip was left in situ for 30 s and 
immediately transferred, for volume determination, to the electronic analyzer Periotron® 8000 
(OraFlow Inc.). 
Before starting the measurements the Periotron® was calibrated with a sterile strip, according 
to the manufacturer's instructions. The two plates were cleaned with sterile gauze among a 
sample and the other. 
The gingival crevicular fluid sample was collected before and after the non-cleaning phase at 
the same time to exclude variation due to the fluctuation of the concentration of IL-1β within 
the 24 hours (23). 
If a strip, after being removed from the gingival sulcus, had presented an obvious blood 
contamination, it was removed and, after at least 60 s, the collection was repeated. 
The scores provided by Periotron® were converted to microliters (mL) using the equation that 
best describes the calibration curve (30). 
Interleukin-1β assay  
The biomolecular research was conducted in the laboratories of the section of General 
Pathology, Department of Medicine and Experimental Oncology, University of Turin. 
Each strip, removed from the Periotron®, was immediately placed in a polypropylene test tube 
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containing 350 mL of a buffer solution, phosphate buffered saline. The tubes (Micro Test 
Tubes, Eppendorf AG, Hamburg, Germany) were kept at room temperature and occasionally 
stirred. After 60 min, the strips were removed from the test tubes, which were stored at -80°C.  
The tubes were thawed and the phosphate-buffered saline contained inside was centrifuged at 
2700 g for 5 min so the epithelial residues, dissolved in solution, adhered to only one wall. 
The supernatant was transferred to a new tube, preventing the tip contacted the walls of the 
tube. 
The level of IL-1β in the gingival crevicular fluid was determined using the Human IL-1β 
Instant enzyme-linked immunosorbent assay kit (Bender MedSystem GmbH, Wien, Austria), 
according to the manufacturer’s instruction. 
The test sensitivity is 0.7 pg/ml and the resulting standard curve expresses the IL-1β values as 
pg/100 mL. The quality and reproducibility of the IL-1β analysis was tested by measuring 
standard solutions with known concentration of IL-1β. 
The IL-1β concentration was then compared to the paper strip elution (350µL). 
Statistical analysis 
The dental site was regarded as the statistical unit. For each clinical and biomolecular 
parameter, the average of the two recordings, from the mid-and mesial-buccal position of all 
the sites of interest, was calculated. These data were obtained for the baseline and after 14 d. 
As the non-Gaussian data distribution, the non-parametric Wilcoxon test was used to analyze 
the changes between baseline and follow-up to 14 d. 
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As the spilt-mouth design of the research, the Wilcoxon test was also used to assess the 
significance of the differences between test and control both at the baseline and after the no-
cleaning phase. P < 0.05 was considered statistically significant. 
The statistical analysis was performed using the software STATPLUS 2009 Professional 5.8.4 
(Analystsoft Inc., Aexandria, VA, USA) 
Results 
Study sample 
The pre-experimental phases of the research and the study design have been summarized in 
the flow chart (Fig. 1). All the patients in the sample (n = 19), previously subjected to 
bilaminar technique for the treatment of gingival recessions, have completed the experimental 
phase of the research and no one needed antibiotics during this period, so there were no drop-
outs.  Measurements of probing depth, clinical attachment loss, bone loss, bleeding on probing 
in all sample groups were undertaken (not shown). The measurements of the parameters 
analyzed in this study from control and test sites are reported as mean ± standard deviation 
(SD) in Table 1.  
Grafts are more resilient than healthy tissues to experimental gingivitis 
First, we wanted to understand whether there was any major change in clinical parameters of 
inflammation 1 year after surgery. At baseline, test and control sites showed homogeneous 
clinical features (P > 0.05). The GI was equal to 0 for all sites, which was a necessary 
requirement to enter the experimental phase. The plaque index and AngBS followed a 
different trend in the sites subjected to bilaminar surgery compared to controls, although the 
	  13	  
	  
difference was not statistically significant. Specifically, treated sites showed a lower AngBS 
and a greater plaque index at baseline, compared with control sites (Fig. 2). 
After the non-cleaning phase, both groups showed a statistically significant increase in all 
parameters (P < 0.05). Interestingly, GI and AngBS were higher in control sites compared to 
grafted tissues (P < 0.05) (Table 1 and Figs 2–4). 
As revealed by key clinical parameters of gingival inflammation such as GI and AngBS, the 
data demonstrate that grafted tissues are less susceptible to experimental gingivitis than 
normal gingival tissues.  
Analysis of biomolecular parameters 
The next step was to investigate whether any differences were present between grafted and 
normal tissues in terms of molecular markers of gingival inflammation. Unlike clinical 
parameters, evaluation of gingival crevicular  fluid volume and IL-1β levels at baseline 
displayed significant differences between the two groups (P < 0.05). The test sites showed a 
mean volume of gingival crevicular fluid and an average amount of IL-1b higher than the 
control sites (Table 2). 
From the analysis of the data distribution based on percentiles, 75% of the test sites had a 
crevicular fluid volume ≤ 0.29 µL vs. ≤ 0.17 µL in control sites. Concerning IL-1β in the 
gingival crevicular fluid, 75% of the test sites showed a concentration ≤ 25.36 pg/350 µL; 
levels of IL-1β were ≤ 22.17 pg/350 µL in 75% of the controls. 
After suspending oral house hygiene for 14 d, the increase of crevicular fluid and IL-1β in the 
control sites was higher than that recorded in the test sites. Therefore, at the end of the 
experimental phase the difference between the two groups was no longer statistically 
significant (Table 2 and Figs 5 and 6). 
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Taken together, the data show that IL-1β remains at higher levels in grafted tissues 1 year after 
surgery, induction of experimental gingivitis associates with a comparable concentration of 
this cytokine in test and control sites. 
Discussion 
In the present study, we demonstrate that the use of SCTG for the repair of gingival recession 
defects does not predispose the grafted tissues to plaque-related inflammation. Interestingly, 
the grafts developed gingivitis to a lesser extent compared to healthy gingival tissues, as 
revealed by clinical evaluation. 
Few data regarding the healing of the areas treated with SCTG are available in the literature; 
specifically, there is no clear understanding as to the biological behavior of grafts in 
physiological conditions and in response to an inflammatory insult. To investigate these 
aspects, a sample for a split-mouth study was selected. The sample was composed of 19 
patients treated successfully for the correction of gingival defects with SCTG. The patients 
were not susceptible to periodontal disease and therefore it was assumed that, after suspending 
oral hygiene operations, they developed an induced gingivitis where the clinical signs of 
inflammation were proportional to plaque accumulation. Clinical and biomolecular parameters 
were used to measure the level of inflammation of periodontal sites 12 mo after treatment with 
SCTG (test) and healthy non-treated gingivae (control) following the induction of plaque- 
related gingivitis. In the present study, we did not evaluate the same parameters before surgery 
in either test or control sites. Although this may represent a study flaw, we believe that the 
assessment of these values before surgery would not be relevant to our aims, i.e. 
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understanding the response of SCTG to plaque accumulation, and would not affect the 
interpretation of the data. 
The results showed that each site, test and control, was clinically healthy at baseline; IL-­‐1β	  was 
present in crevicular fluid of all participants, in agreement with the literature (19). IL-­‐1β	   is 
physiologically present in the crevicular fluid of healthy sites (31) but there are several factors 
underlying the induction of IL-­‐1β	   that may affect its production, including an inflammatory 
response. The regulation of IL-­‐1β	  expression can occur at different stages of protein synthesis, 
from gene modulation to transcription, translation, maturation and secretion of IL-­‐1β	  (32,33). 
We were particularly interested in IL-­‐1β	  because it is a powerful proinflammatory cytokine 
that is known to influence the response of periodontal tissues to environmental stimuli. It is 
produced mainly by macrophages, but also by other cells, including neutrophils, keratinocytes 
and gingival fibroblasts, stimulated by immune-inducing agents such as bacterial 
lipopolysaccharide, endotoxins derived from gram-negative microorganisms and products of 
tissue degradation (34,35). It can also trigger a mechanism of amplification by inducing its 
own gene expression (36). IL-­‐1β	   can activate endothelial cells to increase the diapedesis of 
leukocytes, stimulating the expression of intercellular adhesion molecule-1 (ICAM-1) and 
selectins (37). It is also directly involved in the mechanisms of periodontal destruction, 
whether through fibroblast stimulation to produce prostaglandin E2 (38), collagenase and 
matrix metalloproteinases (39), or by osteoclast proliferation and activation (40). 
The sites subjected to bilaminar surgery showed an average amount of IL-­‐1β	   significantly 
higher than control sites at baseline, although there were no differences regarding clinical 
indexes. This result shows that the grafted areas, despite having reached the criteria for 
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clinical and aesthetic success, had biomolecular alterations compared to untreated sites. This 
might be due to different histological characteristics of the grafted mucosa: for instance, 
vestibular gingiva is characterized by a submucosal membrane, which contains fat cells and 
glandular bodies, all elements that are absent in the palatal mucosa; the latter is characterized 
by a dense and inelastic connective that blends with the periosteum and is rich in fibroblasts 
(9). Therefore, it is possible that the excess of IL-­‐1β	  originates from the grafted fibroblasts, 
which are able to produce IL-­‐1β	   and are enriched in the SCTG (41,42). Additionally, the 
increased amount of IL-­‐1β	   in gingival crevicular fluid may have created a greater osmotic 
gradient that drew fluids in the gingival sulcus (43), which could explain the higher gingival 
crevicular fluid volume found in the treated sites at baseline. In turn, this increase in crevicular 
fluid might be linked to the introduction of medium and large caliber vessels derived from 
palate, originally not present in the vestibular gingiva. 
After oral house hygiene was suspended for 14 d, both groups showed a statistically 
significant increase of all parameters. The result clearly showed that, in agreement with 
studies conducted over the years, plaque accumulation causes the onset of clinical signs of 
inflammation, increased gingival crevicular fluid volume, and increase of the concentration of 
proin-flammatory cytokines (14,44,45). 
Although at baseline, the test sites were associated with higher biomolecular values regarding 
gingival crevicular fluid volume and the amount of IL-­‐1β, at the end of the experiment control 
and test sites reached the same quantity of IL-­‐1β	  (32); this might either indicate a maximum 
plateau of secretion linked to interleukin-dependent feedback mechanisms, or an increased 
responsiveness of healthy gingival to plaque accumulation, compared with grafted tissues. 
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At the end of experiment, the GI and AngBS appeared statistically higher in control sites. This 
clinical evidence, taken together with histological and immunohistochemical data that show 
loss of vasomotor control due to a decrease in nerve fibers in grafted tissues (13), suggest that 
an attenuated clinical inflammatory response in grafts may be due to an alteration of the 
mechanisms of “neurogenic inflam- mation” (46). The results can be linked to our previous 
data where alteration of sensation in tissue grafts was associated with an increased amount of 
free Merkel cells. Specifically, Merkel cells were absent in normal gingival samples but were 
present in the palatal donor sites, together with a reduction in nerva vasorum (13); these data 
came together with sensorial alteration of the patient when the grafted mucosa was challenged. 
We believe that these findings can be related to the differences in terms of gingival crevicular 
fluid and IL-­‐1β	   observed in the present study. In other words, reduction of neurogenic 
inflammation may account for a compromised vasodilatation, which, in turn, limits the 
responsiveness to plaque accumulation in grafted tissues. In view of our recent data 
demonstrating the production of corticosteroids by fibroblasts (47), including those from the 
gingival mucosa (48), it is also possible that the grafted tissue produces higher levels of 
cortisol thus modulating the local immune response. Further studies are needed to address 
these hypotheses. 
Conclusion 
Collectively, analysis of the data demonstrates that the sites of gingival recession treated with 
SCTG develop a lower degree of plaque-induced inflammation compared to healthy gingivae. 
It is speculated that the presence of larger amounts of connective tissue in gingival mucosa 
becomes a protective factor for bacterial invasion, possibly by limiting the inflammatory 
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response or by inducing a more effective host response. Overall, the sites treated with the 
bilaminar technique retain, after 12 mo, biomolecular and sensorial alterations that will 
deserve further investigation. 
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Table 1. Clinical indexes (Mean ± SD) at baseline and 14 days after 
experimental gingivitis in sites treated with bilaminar technique (Test) 
and in periodontal healthy sites (Control) 
 Test  Control 
Clinical indexes Baseline 14 days  Baseline 14 days 
GI 0,00 ± 0,00 1,05 ± 0,23a  0,00 ± 0,00 1,34 ± 0,47a,b 
PlI 0,13 ± 0,33 2,42 ± 0,61a  0,05 ± 0,16 2,42 ± 0,61a 
AngBS 0,13 ± 0,28 0,34 ± 0,37a  0,24 ± 0,39 0,61 ± 0,39a,b 
AngBS, angulated bleeding score; GI, gingival index; PI, plaque index. 
aSignificantly different from baseline (p < 0,05). 
bSignificantly different from test group (p < 0,05). 
 
 
 
 
 
 
 
Table 2. Biomolecular parameters (Mean ± SD) at baseline and 14 days 
after experimental gingivitis in sites treated with bilaminar technique 
(Test) and in periodontal healthy sites (Control) 
 Test  Control 
Biomolecular 
parameters Baseline 14 days  Baseline 14 days 
GCF volume (µL) 0,24 ± 0,17 0,47 ± 0,27a  0,18 ± 0,13 b 0,42 ± 0,21a 
IL-1β (pg/350µL) 19,87 ± 14,02 50,09 ± 26,04a  15,53 ± 9,48 b 51,57 ± 38,73a 
aSignificantly different from baseline (p < 0,05). 
bSignificantly different from test group (p < 0,05). 
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Fig. 2.  
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Fig. 3.  
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Fig. 4.  
 
 
Fig. 5 
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Fig. 6.  
 
 
 
Legends 
 
Figure 1:  Flow chart 
 
Figure 2: Histogram representing the trend of gingival index. 
 
Figure 3: Histogram representing the trend of the plaque index 
 
Figure 4: Histogram representing the trend of the angulated bleeding score 
 
Figure 5: Histogram representing the trend of the gingival crevicular fluid volume (µL). 
 
Figure 6: Histogram representing the trend of interleukin-1β concentration. 
